Yes Routy1, very nice. Qiagen of course had a net turnover of USD 372.1mln in Q1 so still a tat larger than our NCYT. I would say by about a factor 9? However, if that means we should be looking for a ninth of USD 11.5 bln as a takeover price then so be it. I think I can live with that. MS
Steve1964, reading through this BB you really stand out. within half a trading day you've gone from £1 this month to £2.5 by lunch time to £1.6 by close today and thereafter massively up so sell the house etc and buy... Trying to make up you mind?? MS
Hi Bramley, there must be a reason for that approach. It is certainly always good to bring ones house in order. However, the way they have approached this is cleaning themselves up for whatever comes next. If it's a buyout then great. And why not? The company certainly is good at creating business and being ahead of the curve. Can you imagine if you are attached to a big pharma what that ahead of the curve would mean? Lot faster at attracting other big companies.... If it's not a buy out, it's just great to have the debt paid off and our house in order so we don't loose any penny unnecessarily. MS
And don't forget that the CEO of Roche said in an interview with a Swiss newspaper two weeks ago that the demand for their tests was greater than their production capacity so they were looking to expand. Surely our position will be very similar. MS
Again, as I posted yesterday, Christoph Franz, CEO of Roche, said in a Swiss newspaper that they cannot keep up with demand for covid-19 tests. There are only two WHO approved tests. We are one of them. If Roche can't make enough, do you really think we are not selling everything we can produce? Just sit back and let the news come to you. MS
Roche can't keep up with demand for tests28 Jun 2020 23:17
Roche's CEO Christoph Franz has stated in an interview with the swiss newspaper Tages Anzeiger that Roche cannot keep up with demand foir their Covid 19 PCR tests and that production has to be extended.
He even went as far as stating that Roche now determines who gets the tests and who doesn't by evaluating who needs it most. Can you imagine being in a position like that. Crazy...
If you ever had any doubts of how big the demand for NCYT tests actually is this then this is your sign to let go. We can't ask for a more convincing statement than what Christoph gave us. Competitor yes, but same market. They can't supply enough, so neither can we.
SS: well I'm certainly not going to hide behind bs stories like you just did. Been here too long to believe that spin. And for the record, I didn't insult you, that was just a dumb post you made. If you don't like criticism then don't put it out there. MS
Although it is good I think to get rid of Atlas like this, I wonder why they have to place now. There is still more than 5 weeks on the clock to do just that?? And wasn't there still an election to make for Atlas? 'The Election'? And what is the difference between Atlas getting the shares and this placing, it's both shares out into the market? 6 and two 3s springs to mind.
So, raising a lot of money that is not needed for 5 weeks at the very least (which in this company is a very, very long time) sounds odd to me. AP is raising again because they are out of money and did not plan properly. Again.
Don't be surprised that when Atlas Elects to convert in July, AP does not have the money any more and shares will be allocated to Atlas anyway. It fits very well with the history of AP. You can remind me in August if I'm wrong! If we are close to production at that time and PI can see the light of revenue then it may not hurt the Sp too much either, but that ios what I expect hence the very early placing now. MS
Prop, if the WHO is going to get behind the Covid fight in Brazil (or SA and LA as a whole), then there will be a push for the Primer test to be used. Doubt Brazil will get through this alone. So do we really need that many sales people in the region? MS
So, we are selling to 130 countries and make some 10mln tests per month at 50% margin. Just seen on the news that India is drowning in covid-19 cases. Same in Brazil. However, most cannot get tested as cost are too high.
From a commercial perspective, would it not be a lot more sensible for NCYT to reduce their margin while increasing the sales dramatically? Larger part of a larger pie... Surely there is a price sensitivity. Reduce margin by 50% and increase sales by 200%. You get to the same profit but you drown everyone else out. You can even make great show with the low margin made compared to others. MS
Well gggg21, I do a lot of research also and base my decisions on that info. But I'm also not stating news is incoming and then not post it as in my view statements like that lack credibility. But it's not my credibility that is at stake here. Obviously I haven't found what blade claims to have found. Anyway,if it makes people feel important to make these statements then so be it. I'm here for my reasons, regardless of what others post or state. Just find it very odd. MS